2019
Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients
James JA, Chen H, Young KA, Bemis EA, Seifert J, Bourn RL, Deane KD, Demoruelle MK, Feser M, O'Dell JR, Weisman MH, Keating RM, Gaffney PM, Kelly JA, Langefeld CD, Harley JB, Robinson W, Hafler DA, O'Connor KC, Buckner J, Guthridge JM, Norris JM, Holers VM. Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. EBioMedicine 2019, 42: 76-85. PMID: 30952617, PMCID: PMC6491794, DOI: 10.1016/j.ebiom.2019.03.063.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusFirst-degree relativesGenetic risk scoreRA patientsRheumatoid arthritisSLE patientsT1D patientsAutoantibody-positive systemic lupus erythematosusRisk first-degree relativesOrgan-specific autoimmune diseasesType 1 diabetes patientsAutoimmune disease preventionAnti-tissue transglutaminaseDisease-associated autoantibodiesDisease prevention studiesUnaffected first-degree relativesCross-sectional studyLatent autoimmunityLupus erythematosusAutoimmune diseasesDiabetes patientsPrevention StudyRisk scoreAutoimmunityPreclinical period
1996
Antigen-specific therapies for the treatment of autoimmune diseases
Hafler D, Weiner H. Antigen-specific therapies for the treatment of autoimmune diseases. 1996, 61-76. DOI: 10.1007/978-3-642-61191-9_6.Peer-Reviewed Original ResearchAntigen-specific therapyInfectious agentsMajor histocompatibility complexAutoimmune disordersAutoimmune diseasesT cellsLocal antigen-presenting cellsOrgan-specific autoimmune diseasesHuman autoimmune disordersAntigen-presenting cellsOrgan-specific proteinsRange of antigensAutoimmune processAutoimmune cascadeHistocompatibility complexDisordersTherapyDiseasePrimary targetCellsVirusOrgansAgentsSuperantigensEtiology
1994
Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens
Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA. Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens. Annual Review Of Immunology 1994, 12: 809-837. PMID: 8011298, DOI: 10.1146/annurev.iy.12.040194.004113.Peer-Reviewed Original ResearchConceptsOrgan-specific autoimmune diseasesExperimental autoimmune encephalomyelitisAntigen-specific fashionOral toleranceRegulatory cellsSuppressive cytokinesAutoimmune diseasesClonal anergyHuman organ-specific autoimmune diseasesGut-associated lymphoid tissueAntigen-nonspecific fashionExperimental autoimmune modelsTh2-type responsePositive clinical effectsProlong graft survivalPeripheral immune toleranceT cell autoreactivityInitial clinical trialsAntigen-induced toleranceActive suppressionOral tolerizationSuppress alloreactivityGraft survivalNOD miceAutoimmune encephalomyelitis
1993
Suppression of Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens
Weiner H, Miller A, Khoury S, Zhang Z, Al-Sabbagh A, Brod S, Lider O, Higgins P, Sobel R, Matsui M, Sayegh M, Carpenter C, Eisenbarth G, Nussenblatt R, Hafler D. Suppression of Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens. 1993, 627-634. DOI: 10.1007/978-3-642-51479-1_81.Peer-Reviewed Original ResearchSuppressor T cellsAutoimmune diseasesOral administrationPeyer's patchesT cellsEpithelial cellsImmune systemAntigen-specific suppressor T cellsOrgan-specific autoimmune diseasesHuman gut epithelial cellsAutoreactive immune processesSpecific suppressor cellsPeripheral immune toleranceAntigen-presenting cellsClass II antigensAnti-idiotypic antibodiesAntigen-induced toleranceIntestinal epithelial cellsGut epithelial cellsHen's egg proteinsAutoimmune processOral toleranceSuppressor cellsImmune toleranceImmunologic tolerance